CORP-2
COlchicine for Recurrent Pericarditis 2 — multiple recurrences
Patient / Population Intervention / Exposure Comparison Outcome
In 240 patients with at least two prior recurrences of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy reduced further recurrent pericarditis compared with placebo.
N
240
Design
Double-blind, placebo-controlled RCT
Endpoint
Recurrent pericarditis (intention-to-treat)
Relevance
2
Result21.6 % vs 42.5 % (RR 0.49; 95 % CI 0.24–0.65; p=0.0009; NNT 5). No serious adverse events.
Imazio M, Belli R, Brucato A, et al. Lancet. 2014;383(9936):2232-2237. 10.1016/S0140-6736(13)62709-9
Discussion & critique
Four northern-Italian hospitals and a predominantly idiopathic case mix, with open follow-up beyond six months limiting inference about optimal duration. It closed the last gap in the colchicine story and extends the drug to every colchicine-naïve relapse, however many have gone before.